Suppr超能文献

[心律失常与淀粉样变性]

[Cardiac arrhythmias and amyloidosis].

作者信息

Salinas-Arce Jorge, Alca-Clares Raúl, Gonzales-Luna Ana Cecilia, Cabrera-Saldaña Mario, Mendoza-Novoa Pablo, Solórzano-Altamirano Paula, Guevara-Valdivia Milton

机构信息

Unidad de Arritmias, Clínica Delgado. Lima, Perú. Unidad de Arritmias Clínica Delgado Lima Perú.

. Servicio de Cardiología, Hospital Cayetano Heredia. Lima, Perú. Servicio de Cardiología Hospital Cayetano Heredia Lima Perú.

出版信息

Arch Peru Cardiol Cir Cardiovasc. 2022 Jun 27;3(2):82-97. doi: 10.47487/apcyccv.v3i2.217. eCollection 2022 Apr-Jun.

Abstract

Cardiac amyloidosis (CA) is a form of cardiomyopathy characterized by the extracellular deposit of protein fibers in the myocardium, leading to the development of heart failure, arrhythmias, and electrical conduction system alterations. It is known that most cardiomyopathies have a close relationship with heart rhythm abnormalities, however, CA is specially related to different kinds of arrhythmias even in pre-diagnosis stages. Arrhythmias like atrial fibrillation are present in up to 70% of patients with CA associated with a high risk of cardioembolic complications independent of the risk stratification. Ventricular arrhythmias are frequent, but the use of implantable cardioverter defibrillator has not been demonstrated to improve survival. The Atrial-Ventricular node disease is also common, and is frequently associated with the implantation of a pacemaker, even in asymptomatic patients. In this review, we clarify the recommendations of the most current guidelines, summarize historical and contemporaneous data and describe evidence-based strategies for the management of arrhythmias and their complications in CA.

摘要

心脏淀粉样变性(CA)是一种心肌病,其特征是心肌中细胞外蛋白质纤维沉积,导致心力衰竭、心律失常和电传导系统改变。已知大多数心肌病与心律异常密切相关,然而,即使在预诊断阶段,CA也与各种心律失常特别相关。心房颤动等心律失常在高达70%的CA患者中出现,与心脏栓塞并发症的高风险相关,与风险分层无关。室性心律失常很常见,但植入式心脏复律除颤器的使用尚未被证明能提高生存率。房室结疾病也很常见,即使在无症状患者中也经常与起搏器植入相关。在本综述中,我们阐明了最新指南的建议,总结了历史和同期数据,并描述了CA中心律失常及其并发症管理的循证策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c1/10284580/b47ee4a6161a/apcyccv-3-82-g001.jpg

相似文献

1
[Cardiac arrhythmias and amyloidosis].
Arch Peru Cardiol Cir Cardiovasc. 2022 Jun 27;3(2):82-97. doi: 10.47487/apcyccv.v3i2.217. eCollection 2022 Apr-Jun.
2
Management of Arrhythmias in Cardiac Amyloidosis.
JACC Clin Electrophysiol. 2020 Apr;6(4):351-361. doi: 10.1016/j.jacep.2020.01.004.
3
Electrophysiological Manifestations of Cardiac Amyloidosis: State-of-the-Art Review.
JACC CardioOncol. 2021 Oct 19;3(4):506-515. doi: 10.1016/j.jaccao.2021.07.010. eCollection 2021 Oct.
4
[Arrhythmias and amyloidosis].
Herzschrittmacherther Elektrophysiol. 2024 Sep;35(3):199-204. doi: 10.1007/s00399-024-01016-y. Epub 2024 May 13.
6
Arrhythmias in Cardiac Amyloidosis: Challenges in Risk Stratification and Treatment.
Can J Cardiol. 2020 Mar;36(3):416-423. doi: 10.1016/j.cjca.2019.11.039. Epub 2019 Dec 12.
7
Cardiac Implantable Electronic Devices: A Window Into the Evolution of Conduction Disease in Cardiac Amyloidosis.
JACC Clin Electrophysiol. 2020 Sep;6(9):1144-1154. doi: 10.1016/j.jacep.2020.04.020. Epub 2020 Aug 26.
8
Sustained ventricular arrhythmia and sinus node dysfunction revealing a cardiac amyloidosis: A case report.
Ann Med Surg (Lond). 2022 Nov 12;84:104888. doi: 10.1016/j.amsu.2022.104888. eCollection 2022 Dec.
9
Association of Arrhythmias in Cardiac Amyloidosis and Cardiac Sarcoidosis.
Cureus. 2020 Aug 18;12(8):e9842. doi: 10.7759/cureus.9842.
10
Arrhythmias and Device Therapies in Cardiac Amyloidosis.
J Clin Med. 2024 Feb 25;13(5):1300. doi: 10.3390/jcm13051300.

引用本文的文献

1
Monoclonal gammopathy progressing to systemic amyloidosis with cardiac involvement. A case report.
Arch Peru Cardiol Cir Cardiovasc. 2025 Jun 27;6(2):104-109. doi: 10.47487/apcyccv.v6i2.477. eCollection 2025 Apr-May.
2
Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review.
Cardiol Res. 2024 Aug;15(4):211-222. doi: 10.14740/cr1664. Epub 2024 Jul 18.

本文引用的文献

1
Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis.
Int J Cardiol. 2022 Jul 1;358:65-71. doi: 10.1016/j.ijcard.2022.04.045. Epub 2022 Apr 18.
3
Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.
ESC Heart Fail. 2022 Jun;9(3):1740-1748. doi: 10.1002/ehf2.13851. Epub 2022 Feb 17.
5
New Oral Anticoagulants vs. Vitamin K Antagonists Among Patients With Cardiac Amyloidosis: Prognostic Impact.
Front Cardiovasc Med. 2021 Nov 30;8:742428. doi: 10.3389/fcvm.2021.742428. eCollection 2021.
6
Electrophysiological Manifestations of Cardiac Amyloidosis: State-of-the-Art Review.
JACC CardioOncol. 2021 Oct 19;3(4):506-515. doi: 10.1016/j.jaccao.2021.07.010. eCollection 2021 Oct.
7
Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis: A systematic review.
Pacing Clin Electrophysiol. 2021 Dec;44(12):2092-2099. doi: 10.1111/pace.14375. Epub 2021 Oct 24.
8
Cardiac Implantable Electronic Devices: A Window Into the Evolution of Conduction Disease in Cardiac Amyloidosis.
JACC Clin Electrophysiol. 2020 Sep;6(9):1144-1154. doi: 10.1016/j.jacep.2020.04.020. Epub 2020 Aug 26.
9
Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
Am J Cardiol. 2020 Aug 1;128:140-146. doi: 10.1016/j.amjcard.2020.05.021. Epub 2020 May 16.
10
Management of Arrhythmias in Cardiac Amyloidosis.
JACC Clin Electrophysiol. 2020 Apr;6(4):351-361. doi: 10.1016/j.jacep.2020.01.004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验